Morgan Stanley Issues Pessimistic Forecast for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN) had its price target decreased by Morgan Stanley from $45.00 to $25.00 in a research note released on Friday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other brokerages have also weighed in on SLN. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. Chardan Capital decreased their price objective on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a report on Friday. BMO Capital Markets cut their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group reduced their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.83.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $3.70 on Friday. Silence Therapeutics has a 52 week low of $1.97 and a 52 week high of $24.38. The firm has a 50-day moving average price of $3.39 and a two-hundred day moving average price of $6.57. The firm has a market cap of $110.74 million, a price-to-earnings ratio of -2.36 and a beta of 1.20.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. As a group, sell-side analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of large investors have recently modified their holdings of SLN. GAMMA Investing LLC lifted its stake in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Silence Therapeutics in the fourth quarter worth $120,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Silence Therapeutics in the fourth quarter worth $69,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Silence Therapeutics during the fourth quarter valued at $134,000. Finally, JPMorgan Chase & Co. purchased a new position in Silence Therapeutics during the fourth quarter worth about $26,000. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.